Search

everythinglearnresearchcommunity

for

Search:↓

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

People with alopecia areata have fewer regulatory T-cells than those with other skin conditions.

Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.

CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.

Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

Human hair follicles have a unique way of using energy and might use the Cori cycle; blocking CCR5 could help treat hair loss.

Memory regulatory T cells need IL-7, not IL-2, to stay in peripheral tissues.

Hair loss in mice starts with immune cells damaging hair roots before it becomes visible.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

T-cell reconstitution after thymus transplantation can cause hair whitening and loss.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.

Alopecia areata involves specific immune cells, offering potential treatment targets.

Bullous pemphigoid is influenced by genetic factors, immune cell dysfunction, aging, and triggers, with treatment often improving symptoms.

Both treatments for alopecia areata are equally effective and safe.

Tenofovir is more effective than adefovir for resistant hepatitis B, Fibroscan is good for assessing liver damage, regulatory T cells may help hepatitis C persist, and other insights into liver health and disease were found.

ALDOA levels drop in hair cells during hair loss.

The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.

Foxp3 is crucial for regulatory T cell function, and targeting these cells may help treat immune disorders.

CRAC channels are crucial for the development and function of specialized immune cells, preventing severe inflammation and autoimmune diseases.

High leptin levels may promote skin cancer and inflammation, suggesting potential for leptin-targeted therapies.

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.

CBD can either promote or inhibit hair growth depending on the concentration used.

Scarred skin in lichen planopilaris loses immune cells due to a decrease in a specific protein in skin cells.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

Regulatory T cells are essential for normal and improved wound healing in mice.